Achim Leo Burger1, Stefan Stojkovic1, André Diedrich2, Svitlana Demyanets3, Johann Wojta4, Thomas Pezawas1. 1. Medical University of Vienna, Department of Medicine II, Division of Cardiology, Austria. 2. Departments of Medicine, Clinical Pharmacology, Pharmacology, and Neurology, Vanderbilt Autonomic Dysfunction Center, Nashville, TN, United States. 3. Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria. Electronic address: svitlana.demyanets@meduniwien.ac.at. 4. Medical University of Vienna, Department of Medicine II, Division of Cardiology, Austria; Core Facilities, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Cardiovascular Research, Vienna, Austria.
Abstract
INTRODUCTION: Elevated plasma levels of asymmetric dimethylarginine (ADMA), an inhibitor of NO synthase, are associated with adverse outcome. There is no data available, whether ADMA levels are associated with arrhythmic death (AD) in patients with ischemic cardiomyopathy (ICM) or non-ischemic, dilated cardiomyopathy (DCM). METHODS AND RESULTS: A total of 110 ICM, 52 DCM and 30 control patients were included. Primary outcome parameter of this prospective study was arrhythmic death (AD) or resuscitated cardiac arrest (RCA). Plasma levels of ADMA were significantly higher in ICM (p < 0.001) and in DCM (p < 0.001) patients compared to controls. During a median follow-up of 7.0 years, 62 (32.3%) patients died. AD occurred in 26 patients and RCA was observed in 22 patients. Plasma levels of ADMA were not associated with a significantly increased risk of AD or RCA in ICM (hazard ratio (HR) = 1.37, p = 0.109) or in DCM (HR = 1.06, p = 0.848) patients. No significant association was found with overall mortality in ICM (HR = 1.39, p = 0.079) or DCM (HR = 1.10, p = 0.666) patients. Stratified Kaplan-Meier curves for ADMA levels in the upper tertile (>0.715 µmol/l) or the two lower tertiles (≤0.715 µmol/l) did not show a higher risk for AD or RCA (p = 0.221) or overall mortality (p = 0.548). In patients with left ventricular ejection fraction ≤ 35%, ADMA was not associated with AD or RCA (HR = 1.35, p = 0.084) or with overall mortality (HR = 1.24, p = 0.162). CONCLUSIONS: Plasma levels of ADMA were elevated in patients with ICM or DCM as compared to controls, but were not significantly predictive for overall mortality or the risk for arrhythmic death.
INTRODUCTION: Elevated plasma levels of asymmetric dimethylarginine (ADMA), an inhibitor of NO synthase, are associated with adverse outcome. There is no data available, whether ADMA levels are associated with arrhythmic death (AD) in patients with ischemic cardiomyopathy (ICM) or non-ischemic, dilated cardiomyopathy (DCM). METHODS AND RESULTS: A total of 110 ICM, 52 DCM and 30 control patients were included. Primary outcome parameter of this prospective study was arrhythmic death (AD) or resuscitated cardiac arrest (RCA). Plasma levels of ADMA were significantly higher in ICM (p < 0.001) and in DCM (p < 0.001) patients compared to controls. During a median follow-up of 7.0 years, 62 (32.3%) patients died. AD occurred in 26 patients and RCA was observed in 22 patients. Plasma levels of ADMA were not associated with a significantly increased risk of AD or RCA in ICM (hazard ratio (HR) = 1.37, p = 0.109) or in DCM (HR = 1.06, p = 0.848) patients. No significant association was found with overall mortality in ICM (HR = 1.39, p = 0.079) or DCM (HR = 1.10, p = 0.666) patients. Stratified Kaplan-Meier curves for ADMA levels in the upper tertile (>0.715 µmol/l) or the two lower tertiles (≤0.715 µmol/l) did not show a higher risk for AD or RCA (p = 0.221) or overall mortality (p = 0.548). In patients with left ventricular ejection fraction ≤ 35%, ADMA was not associated with AD or RCA (HR = 1.35, p = 0.084) or with overall mortality (HR = 1.24, p = 0.162). CONCLUSIONS: Plasma levels of ADMA were elevated in patients with ICM or DCM as compared to controls, but were not significantly predictive for overall mortality or the risk for arrhythmic death.
Authors: Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews Journal: N Engl J Med Date: 2002-03-19 Impact factor: 91.245
Authors: Mathieu Kruska; Ibrahim El-Battrawy; Michael Behnes; Martin Borggrefe; Ibrahim Akin Journal: Curr Pharm Biotechnol Date: 2017 Impact factor: 2.837
Authors: Catherine N Marti; Mihai Gheorghiade; Andreas P Kalogeropoulos; Vasiliki V Georgiopoulou; Arshed A Quyyumi; Javed Butler Journal: J Am Coll Cardiol Date: 2012-09-19 Impact factor: 24.094
Authors: Friedrich Schulze; Reinhard Wesemann; Edzard Schwedhelm; Karsten Sydow; Jennifer Albsmeier; John P Cooke; Rainer H Böger Journal: Clin Chem Lab Med Date: 2004 Impact factor: 3.694
Authors: Stefan Stojkovic; Robin Ristl; Fabian T Moser; Michael Wolzt; Johann Wojta; Herwig Schmidinger; Thomas Pezawas Journal: Circ J Date: 2014-12-05 Impact factor: 2.993
Authors: Thomas Pezawas; Michael Grimm; Robin Ristl; Danijel Kivaranovic; Fabian T Moser; Guenther Laufer; Herwig Schmidinger Journal: Transpl Int Date: 2015-01 Impact factor: 3.782
Authors: Chiara Volani; Johannes Rainer; Vinicius Veri Hernandes; Viviana Meraviglia; Peter Paul Pramstaller; Sigurður Vidir Smárason; Giulio Pompilio; Michela Casella; Elena Sommariva; Giuseppe Paglia; Alessandra Rossini Journal: Metabolites Date: 2021-03-25